ANANDA Scientific Announces a Clinical Trial Evaluating Nantheia™ ATL5, in the treatment of Co-Occurring Opioid Use Disorder and Chronic Pain

Contributed by: Business Wire

Logo

Images

(Photo: Business Wire)

Business Wire embedded0

Tags

Research

Neurology

Cannabis

Clinical Trials

Biotechnology

Health

Pharmaceutical

Science

Natural Resources

Nantheia ATL5

More Like This

(Photo: Business Wire)

ANANDA Scientific and the David Geffen School of Medicine, UCLA, Announce Commencement of a Clinical Trial Evaluating Nantheia™ ATL5 for Smoking Cessation

PR Newswire associated0

AmacaThera doses First In Human Study to Evaluate, AMT-143, for Non-opioid Treatment of Post-operative Pain

PR Newswire associated0

AmacaThera Announces Phase 1 Results of First-in-Human Study with AMT-143, Exceeding Expectations and Paving the Way for a Novel Approach to Post-Operative Pain Relief

CBD is approved for treatment-resistant epilepsy in children, and recent trials suggest that it may be useful for treating other disorders, such as schizophrenia and anxiety. Photo credit: Julia Zolotova

Quolet announces completion of Phase 1 healthy volunteer study evaluating the safety and bioavailability of Cannabidiol in a novel formulation intended for treatment of various neurological and psychiatric diseases

Avata Biosciences Emerges to Develop Solid Dose Cannabinoid Medicines for Epilepsy and Other Neurological Diseases

PR Newswire associated0

Tetra Pharm Technologies introduces pain relieving drug in the United Kingdom

Sapient Therapeutics Announces Positive Phase 1 Results in Part B of Its Solid Dose Prescription CBD Study

Tilray Medical Announces Positive Results from Study on Oral Cannabis Extract for Chemotherapy-Induced Emesis